Antitussive Drugs—Past, Present, and Future
- 3 March 2014
- journal article
- review article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Pharmacological Reviews
- Vol. 66 (2), 468-512
- https://doi.org/10.1124/pr.111.005116
Abstract
Cough remains a serious unmet clinical problem, both as a symptom of a range of other conditions such as asthma, chronic obstructive pulmonary disease, gastroesophageal reflux, and as a problem in its own right in patients with chronic cough of unknown origin. This article reviews our current understanding of the pathogenesis of cough and the hypertussive state characterizing a number of diseases as well as reviewing the evidence for the different classes of antitussive drug currently in clinical use. For completeness, the review also discusses a number of major drug classes often clinically used to treat cough but that are not generally classified as antitussive drugs. We also reviewed a number of drug classes in various stages of development as antitussive drugs. Perhaps surprising for drugs used to treat such a common symptom, there is a paucity of well-controlled clinical studies documenting evidence for the use of many of the drug classes in use today, particularly those available over the counter. Nonetheless, there has been a considerable increase in our understanding of the cough reflex over the last decade that has led to a number of promising new targets for antitussive drugs being identified and thus giving some hope of new drugs being available in the not too distant future for the treatment of this often debilitating symptom.Keywords
This publication has 105 references indexed in Scilit:
- Antihistaminergics and inverse agonism: Potential therapeutic applicationsEuropean Journal of Pharmacology, 2013
- Anti-tussive and bronchodilator mechanisms of action for the enaminone E121Life Sciences, 2011
- Central sensitization: Implications for the diagnosis and treatment of painPain, 2011
- Pharmacological profile of the NOP agonist and cough suppressing agent SCH 486757 (8-[Bis(2-Chlorophenyl)Methyl]-3-(2-Pyrimidinyl)-8-Azabicyclo[3.2.1]Octan-3-Ol) in preclinical modelsEuropean Journal of Pharmacology, 2010
- Central regulation of the cough reflex: Therapeutic implicationsPulmonary Pharmacology & Therapeutics, 2009
- Older-Generation Antihistamines and Cough Due to Upper Airway Cough Syndrome (UACS): Efficacy and MechanismLung, 2007
- The effect of codeine on the Urge-to-Cough response to inhaled capsaicinPulmonary Pharmacology & Therapeutics, 2007
- Risk of Community-Acquired Pneumonia and Use of Gastric Acid–Suppressive DrugsJAMA, 2004
- M1 muscarinic antagonists interact with σ recognition sitesLife Sciences, 1991
- GABA-receptors in peripheral tissuesLife Sciences, 1990